Close mobile menu×
Close mobile menu

Cheryl H. Waters, MD

Board Certifications: 
Neurology
Accepting New Patients
Profile Headshot

Appointments

Phone Appointments

New and Existing Patients: 
(212) 305-1303

myColumbiaDoctors

For existing patients, login to make an appointment, view documentation or contact your care provider.

Credentials & Experience

America's Top Doctor

Board Certifications

  • Neurology

Clinical Expertise

  • Parkinson's Disease
  • Movement Disorder

Specialties

Education & Training

  • University of Toronto Faculty of Medicine
  • Residency: University of Toronto Hospitals
  • Fellowship: University of Toronto Hospitals

About Cheryl Waters

Cheryl Waters MD FRCP(C), holds bachelors and masters degrees in Pharmacology from the University of Toronto, where she studied dopamine receptor function with Philip Seeman. She completed medical school at University of Toronto, an internship at University of Chicago, and returned to Toronto for Internal Medicine, Neurology and a fellowship in Clinical Pharmacology. She moved to California and developed the Movement Disorder Program at the University of Southern California. Dr. Waters then moved to New York to take on her current position as Chief of Clinical Practice and Services in the Division of Movement Disorders. She has been involved in research on the genetics of Parkinson's disease and the treatment of this disorder. She has authored numerous articles and book chapters and a book just printed in its sixth edition: Diagnosis and Management of Parkinson's Disease. She has been an investigator in numerous studies involving a variety of new medical and surgical treatments. She is the first to hold the Albert B. and Judith L. Glickman Chair in Neurology.

Academic Titles

  • Albert B. and Judith L. Glickman Professor of Neurology at CUMC

Hospital Affiliations

  • NewYork-Presbyterian/Columbia

Gender

  • Female

Insurance Accepted

Aetna

  • EPO
  • HMO
  • Medicare Managed Care
  • NY Signature
  • POS
  • PPO
  • Signature Administrators
  • Student Health

Affinity

  • Access (Exchange)
  • Essential Plan
  • Medicaid Managed Care

Amida Care

  • Special Needs Plan

Cigna

  • EPO
  • Great West
  • HMO
  • POS
  • PPO

Empire Blue Cross Blue Shield

  • Blue Priority
  • EPO
  • HMO
  • Medicare (Mediblue)
  • NYP Employee Plan
  • Pathway (Exchange)
  • POS
  • PPO

Empire Blue Cross Blue Shield HealthPlus

  • Child/Family Health Plus
  • Essential Plan
  • Medicaid Managed Care

Fidelis Care

  • Child/Family Health Plus
  • Medicaid Managed Care

Healthfirst

  • Child/Family Health Plus
  • Medicaid Managed Care

Local 1199

MagnaCare

Medicare

Oxford Health Plans

  • Freedom
  • Liberty

POMCO

UnitedHealthcare

  • Columbia University Employee Plan
  • EPO
  • HMO
  • Medicaid (Community Plan)
  • POS
  • PPO

VNSNY CHOICE

  • SelectHealth

*Please contact the provider’s office directly to verify that your particular insurance is accepted.

Contact & Locations

1
710 West 168th Street
New York, New York 10032
Phone:
(212) 305-3665
Fax:
(212) 305-1304
Primary
2
155 White Plains Road
Suite W100
Tarrytown, New York 10591
Phone:
(914) 366-4200

Research

Grants

A PHASE 3, RANDOMIZED, DOUBLE BLIND, PLACEBO CONTROLLED STUDY INVESTGATING THE EFFICACY AND SAFETY OF CVT 301 (LEVODOPA INHALATION POWDER) IN PARKINSON''S DISEASE PATIENTS WITH MOTOR RESPONSE FLUCTUATIONS (OFF PHENOMENA) (P&S Industry Clinical Trial)

Apr 1 2015 - Apr 1 2020

" A PHASE 3, 12-WEEK, DOUBLE-BLIND, PLACEBO-CONTROLLED, RANDOMIZED, MULTICENTER STUDY TO EVALUATE THE EFFICACY OF ORAL ISTRADEFYLLINE 20 AND 40 MG/DAY AS TREATMENT FOR SUBJECTS WITH MODERATE TO SEVERE PARKINSON''S DISEASE" (P&S Industry Clinical Trial)

Apr 25 2014 - Apr 25 2019

CLINICAL COORDINATION CENTER FOR STEADY-PD3 (Federal Gov)

Aug 1 2014 - Mar 31 2019

PHASE 3 TRIAL OF INOSINE FOR PARKINSON S DISEASE CCC (Federal Gov)

Sep 1 2015 - Jun 30 2017

SETTLE EXT 28850 (P&S Industry Clinical Trial)

Dec 14 2011 - Dec 14 2016

MOTION EXT (P&S Industry Clinical Trial)

Oct 11 2011 - Oct 11 2016

SYN115-CL02 (P&S Industry Clinical Trial)

Jun 28 2011 - Jun 28 2016

A PHASE 3, DOUBLE-BLIND, PLACEBO- AND ACTIVE-CONTROLLED DOSERANGE-FINDING EFFICACY AND SAFETY STUDY OF PRELADENANT IN (P&S Industry Clinical Trial)

Jan 21 2011 - Jan 21 2016

OPEN-LABEL, 12-MONTH SAFETY AND EFFICACY STUDY OF LEVODOPA- CARBIDOPA INTESTINAL GEL IN LEVODOPA-RESPONSIVE PARKINSON"S (P&S Industry Clinical Trial)

Dec 15 2010 - Dec 15 2015

A PHASE III, DOUBLE-BLIND,PLACEBO-CONTROLLED,RANDOMISED TRIAL TO DETERMINE THE EFFICACY AND SAFETY OF A DOSE RANGE OF 50 (P&S Industry Clinical Trial)

Nov 11 2010 - Nov 11 2015

AFQ056A2216- (P&S Industry Clinical Trial)

Aug 23 2010 - Aug 23 2015

A PHASE III, DOUBLE-BLIND, PLACEBO-CONTROLLED RANDOMISED TRIAL TO DETERMINE THE EFFICACY AND SAFETY OF A LOW AND HIGH (P&S Industry Clinical Trial)

Jul 29 2010 - Jul 29 2015

OPEN-LABEL CONTINUATION TREATMENT STUDY WITH LEVODOPA INSTESTINAL GEL IN SUBJECTS WITH ADVANCED PARKINSON"S DISEASE AND (P&S Industry Clinical Trial)

Jun 15 2010 - Jun 15 2015

AN OPEN LABEL EXTENSION STUDY OF THE SAFETY AND CLINICAL UTILITY OF IPX066 IN SUBJECTS WITH PARKINSON"S DISEASE (P&S Industry Clinical Trial)

Sep 8 2010 - Jun 8 2015

A STUDY TO EVALUATE THE SAFETY AND EFFICACY OF IPX066 IN ADVANCED PARKING''S DISEASE (P&S Industry Clinical Trial)

Nov 16 2009 - Nov 16 2014

A PLACEBO CONTROLLED STUDY TO EVALUATE THE SAFETY AND EFFICACY OF IPX066 IN SUBJECTS WITH PARKINSON''S DISEASE (P&S Industry Clinical Trial)

May 21 2009 - May 21 2014

SOLVAY -- S187 3 004 (P&S Industry Clinical Trial)

Jun 13 2008 - Jun 30 2012

SCHWARTZ BIOS--SP921 (P&S Industry Clinical Trial)

Dec 4 2007 - Jun 30 2012

A RANDOMOZED,DOUBLE-BLIND,DOUBLE-DUMMY, EFFICACY, SAFETY ANDTOLERABILITY STUDY OF LEVODOPA-CARBIDOPA INTESTINAL GEL IN L (P&S Industry Clinical Trial)

May 1 2009 - May 1 2012

EFFECT OF COENZYME Q10 IN PARKINSONS DISEASE - PHASE 3 (QE3) (Federal Gov)

Dec 1 2007 - Nov 30 2011

A LONGITUDINAL OBSERVATIONAL FOLLOW-UP OF THE PRECEPT STUDY COHORT (POSTCEPT) (Federal Gov)

Jan 1 2007 - May 31 2011

TWO YEAR BLINDED ASSESSMENT OPHTHALMOLOGIC SAFETY STUDY OF PRAMIPEXOLE IR VERSUS ROPINIROLE IN EARLY PARKINSON"S (P&S Industry Clinical Trial)

Jul 8 2005 - Dec 31 2010

EVALUATION OF BLOOD BIOSPECTROSCOPY AS A NOVEL DIAGNOSTIC TE ST FOR IDIOPATHIC PARKINSON DISEASE (PD BIOSPEC) (Private)

Aug 4 2009 - Oct 4 2010

ACUPUNCTURE/MOXIBUSTIONS FOR PEROPHERAL IN PTS WITH HIV (Federal Gov)

Jul 1 2005 - Jun 30 2009

Selected Publications

Arkadir D, Greene PE, Waters CH, Moskowitz CB, Sharp ME. Applause sign in clinically overlapping diseases: a case of TDP-43 proteinopathy. Park Relat Disord2013 Aug;19(8):774-5. doi: 10.1016/j.parkreldis.2013.04.016. Epub 2013 May 13.

Alcalay RN, Caccappolo E , Mejia-Santana H , Tang M –X , Rosado L , Orbe Reilly M,Ruiz D , Louis ED , Comella C ,  Nance M , Bressman S , Scott WK , Tanner C , Mickel S , Waters C  et al,  Cognitive and motor function in long duration PARKIN PD. Arch Neurol 2013 Nov 4. doi: 10.1001

Alcalay RN, Mirelman A, Saunders-Pullman R, Tang MX, Mejia Santana H, Raymond D, Roos E, Orbe-Reilly M, Gurevich T, Bar Shira A, Gana Weisz M, Yasinovsky K, Zalis M, Thaler A, Deik A, Barrett MJ, Cabassa J, Groves M, Hunt AL, Lubarr N, San Luciano M, Miravite J, Palmese C, Sachdev R, Sarva H, Severt L, Shanker V, Swan MC, Soto-Valencia J, Johannes B, Ortega R, Fahn S, Cote L, Waters C et al. Parkinson Disease Phenotype in Ashkenazi Jews with and without LRRK2 G2019S mutations. Mov Disord. 10/15/2013.

Hauser RA, Hsu A, Kell S, et al. Extended-release carbidopa – levodopa (IPX066) compared with immediate – release carbidopa – levodopa in patients with Parkinson's disease and motor fluctuations: a phase 3 randomized, double-blind trial. The Lancet Neurology 2013;12: 346-356.

Liu X, Cheng R, Ye X, Verbitsky M, Kisselev S, Mejia-Santana H, Louis ED, Cote LJ, Andrews H, Waters C, Ford B, Fahn S, Marder K, Lee JH and Clark LN. Increased rate of Sporadic and Recurrent Rare Genic Copy Number Variants in Parkinson's Disease among Ashkenazi Jews. Molecular Genetics and Genomic Medicine. 2013. 1(3), 142-154.

Sakanaka K, Waters CH, Levy OA, Louis ED, Chung WK, Marder KS, Alcalay RN.        Knowledge of and interest in genetic results among Parkinson disease patients and caregivers. J Genet Counsel 2013. Doi 10.1007/s10897-013-9618-y

Waters, Cheryl H:  Diagnosis and Management of Parkinson's Disease.  Professional Communications Inc., Caddo, Oklahoma.  7th edition (in press)

Waters C, Smolowitz J: Sexual Dysfunction. In: Parkinson's disease: second edition, CRC press, Pfeiffer R,  Wszolek Z, Ebadi M,Eds, 2013, pp 343-352.

Waters CH and Smolowitz J:  Impaired Sexual Function. In: Parkinson’s Disease and Nonmotor Dysfunction. Pfeiffer RF, Bodis-Wollner I (eds) Humana Press  (Springer Science, New York) 2013, pp 173-187.

Waters C, The Development of the Rotigotine Transdermal Patch: A  Historical Perspective Neurologic Clinics (in press)

Wright, B Waters CH. Continuous Dopaminergic Delivery to Minimize Motor Complications in Parkinson’s Disease. Expert reviews of Neurotherapeutics2013 Jun;13(6):71929. doi: 10.1586/ern.13.47.